"Patient Preferences Explored in Multiple Myeloma Treatment"
An Eastern Cooperative Oncology Group performance status of ≥2 is linked to lower treatment satisfaction in patients with relapsed or refractory multiple myeloma (RRMM), but receiving medication orally is linked to higher satisfaction, according to researchers at the Icahn School of Medicine at Mount Sinai and published and in The Oncologist. The researchers found that an ECOG performance status of ≥2 was linked to lower patient satisfaction and perceived effectiveness of their treatment. “Despite the increasing number of therapeutic choices available for RRMM and routine mention of taking into account patient preferences in treatment selection, there is a dearth of evidence-based data on these patient preferences in RRMM,” said lead author Ajai Chari, MD, associate professor, hematology and medical oncology, Mount Sinai Hospital. He added, “The present study begins to bridge the gap between patient satisfaction and the burden of RRMM treatment to better inform treatment decision making.”
— Ajai Chari, MD, Director, Clinical Research in the Multiple Myeloma Program, Associate Director, Clinical Research, Mount Sinai Cancer Clinical Trials Office, Associate Professor, Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai